Low-dose oral contraceptives can effectively reduce the risk of ovarian cancer risk

American scholars study found, oral low-dose estrogen / progesterone and in 1972, before the introduction of high doses of drugs with the same degree of reduced risk of ovarian cancer results.

University of Pittsburgh, Pennsylvania United States Roberta B. Dr. Ness recent study found that oral low-dose estrogen / progesterone and in 1972, before the introduction of high doses of drugs with the same degree of reduced risk of ovarian cancer results.



The research compared 767 women in epithelial ovarian cancer (the first 6 months of diagnosis) and 1367 age-matched control subjects of the use of oral contraceptives, participants in the age distribution of 20-89 years old. The researchers found that oral contraceptives for 30 years or more of the time, even if the withdrawal, which reduce the risk of ovarian cancer, the role still exists.



Having regard to age, pregnancy, family history of ovarian cancer and race and other factors, the researchers found that reduce the risk of ovarian cancer risk of up to 40%, and from the age of the original factors of oral contraceptives. The study, published on August 1 of the "American Journal of Epidemiology."



Ness told reporters: "All of ovarian cancer risk factors and protective factors are gathered in the vicinity of growing period, but it is older women, ovarian cancer, diseases, onset after the age of 50. If this disease has an incubation period of 30 years, then the women in the a longer period of time under the protection of drugs is not surprising. from a public health point of view, one can provide nearly 10 years the role of chemotherapy in the form of protection is indeed impressive, the above findings are sufficient to prompt there is risk of ovarian cancer patients should be oral contraceptives